New nail for hip fractures tested in seniors

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * directly or indirectly (through a respondent) will have expressed their will to participate in the study by signing and dating the informed consent; * will have reached the age of 65 at the time of signing the informed consent; * he/she will have been diagnosed with a fracture in the pertrochanteric, intertrochanteric or subtrochanteric region of the femur, stable or unstable, not previously treated; * based on the investigator's judgment, he will have a regular indication for surgical treatment with an intramedullary nail; * the fracture will be treated with the Chimaera short nail (length = 180 mm) and one or two telescopic lag screws, according to the manufacturer's instructions for use. Exclusion Criteria: * will undergo surgery to treat the results of a previously treated fracture; * he/she will have been diagnosed with a pathological fracture of oncological origin (primary tumor or skeletal metastasis); * he/she will have been diagnosed with a fracture in the diaphyseal and/or distal region of the femur; * he/she will have been diagnosed with an open fracture (type II and III according to the classification of Gustilo and Anderson) of the proximal femur; * he/she will have been diagnosed with multiple fractures (including bilateral proximal femur fractures); * in the pre-or intra-operative phase it will be decided to treat the fracture with the long version of the Chimaera nail and/or with non-telescopic cephalic screws (fixed length); * will have a medical condition that constitutes a contraindication to treatment with Chimaera according to the manufacturer's instructions for use; * will have a suspected or certified hypersensitivity/allergy to some component of the device that comes into contact with the patient; * will present some clinical condition that, in the Investigator's opinion, could interfere with the procedures of the Clinical Investigation or that could jeopardize the safety of the patient; * at the same time he will be treated with an unauthorized device that cannot be removed without endangering the safety of the patient; * will be participating in other clinical trials or had participated in other clinical trials in the 3 months before signing the informed consent.